• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » The Classic MAOIs: Our Capsule Summaries

The Classic MAOIs: Our Capsule Summaries

November 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Arguably, the most confusing thing about MAOIs is keeping track of which medication is “tranylcypromine” and which is “phenelzine.” The following mnemonics work for me, and perhaps they will for you:

  • Parnate = tranylcypromine. PAR should remind you of golf. Visualize yourself being TRANsported in a golf cart on your way to the green where you will hope to make PAR.

  • Nardil = phenelzine. Convert “NARD” to NERD. NERDs have more PHEN (fun)!

I haven’t bothered with mnemonics for Marplan (isocarboxazid) or EMSAM (selegeline patch); they just don’t seem as perpetually confusing as the others.

Parnate (tranylcypromine). It comes in 10 mg pills, and is the most well-studied of the MAOIs. Dose it as high as 60 mg. Although Dr. Jonathan Cole (in this month’s TCPR interview) does not seem convinced, Parnate tends to cause less sedation, but more insomnia, than Nardil, a difference that was demonstrated recently in the first head-to-head comparison of two medications (Birkenhager et. al., J Clin Psychiatry 2004;65:1505-1510). Parnate is also more likely than Nardil to cause hypertension in combination with tyramine or adrenergic medication. This may be partly due to the fact that Parnate’s chemical structure is more amphetamine-like than any other MAOI.

Nardil (phenelzine). Nardil is the only MAOI that comes in 15 mg tablets, and the target dose is about 1 mg/kg, or 75 mg/day for many patients. It is considered the “high side effect” MAOI, because it causes sedation, weight gain, and sexual dysfunction. You might use Nardil first for particularly agitated patients and for those who seem less likely to follow the MAOI diet to the letter.

Marplan (isocarboxazid). Marplan, like Parnate, comes in 10 mg pills, and is dosed pretty much identically. Marplan was withdrawn from the U.S. market in 1994 for unclear reasons, apparently due primarily to the economics of marketing it. But it was “reapproved” by the FDA under new ownership (Roche Pharmaceuticals) and with a new, more generous maximum approved dose of 60 mg/day (vs. the former 30 mg/day). The scoop on Marplan is that it is better tolerated than Nardil, and a large meta-analysis reported that it has outperformed placebo more robustly than Parnate or Nardil (Thase et. al., Neuropsychopharmacology 1995;12:185-219).

ldepryl (selegiline). For information on the selegiline patch, see the article in this issue. Oral selegiline is approved only as adjunctive treatment for patients with Parkinson’s Disease who are already taking L-Dopa. Nevertheless, it has been used in depression with reasonable success (Bodkin et. al., Psychiatric Ann 2001;31(6):385-391). It comes in 5 mg pills, and at doses no higher than 20 mg/day is MAO-B selective, meaning that it does not require dietary restrictions, though the usual MAOI drug-drug contraindications do apply. The target antidepressant dose is about 45 mg/day.

TCPR VERDICT:
There’s nothing like the classics!
General Psychiatry
    www.thecarlatreport.com
    Issue Date: November 1, 2006
    SUBSCRIBE NOW
    Table Of Contents
    EMSAM: A User-Friendly MAOI?
    The MAOI-Cheese Interaction: A Primer
    The Classic MAOIs: Our Capsule Summaries
    Reflections on the Use of MAOIs
    The First Antidepressant
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2635946985.jpg
      General Psychiatry

      AI in Practice

      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.